Navigation Links
DP-b99 Phase IIb Trial Results to be Presented at the European,Stroke Conference

. The day 90 median change from baseline was 6.0 and 5.0 NIHSS points in the DP-b99 and placebo groups, respectively; the day 90 median change from baseline in patients with entry NIHSS score of 10-16 was 8.0 and 5.0 points in the DP-b99 and placebo groups, respectively (p=0.03).

The trial enrolled patients within the first 9 hours following appearance of stroke symptoms. The data indicate that the effect of DP-b99 on recovery was uniform across the full 9h window, confirming the wide therapeutic window for DP-b99.

The favorable safety and tolerability profile of DP-b99 was confirmed and is in line with D-Pharm's previous clinical experience from the Phase I and IIa studies. There were no significant differences in the number or type of serious adverse events, mortality rate or death causes between the DP-b99 and placebo groups.

These results show that DP-b99 doubled the chances to recover from ischemic stroke, has at least a 9hr therapeutic window and is safe. D-Pharm is planning to commence a pivotal Phase III study of DP-b99 in 2008.

About D-Pharm Ltd.

D-Pharm (www.dpharm.com) is a biopharmaceutical company pioneering the development of lipid-like therapeutics and has generated a rich product pipeline from its drug targeting and discovery technologies, Regulated Activation of Prodrugs (D-RAPTM) and Membrane Active Chelators (MAC). The company expects to discuss the further development of DP-b99 with regulatory authorities in the coming months.

D-Pharm's pipeline includes DP-VPA, a new chemical entity that is a modified and targeted version of valproic acid for epilepsy, bipolar disorder treatment and migraine prophylaxis, currently in Phase II development. DP-460 is in preclinical development intended as an oral, disease-modifying therapy for Alzheimer's disease.

    For further information please contact:


    Tami Horovitz, PhD.

    Tel: +972-8-9385100

 
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Phase IIb Trial Results Presented the European Stroke Conference
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... Hata to its board of directors. ... development is a tremendous asset to our board," said ... officer of Xencor. "Xencor faces a range of opportunities ...
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Calif., Oct. 27 ... beamforming technology, analog-front-end semiconductors and solutions for the ... Ultrasound Beamforming Development Kit.  Based on Samplify,s AutoFocus™ ... solution for the ultrasound front end, from probe ...
... Oct. 27 Solos Endoscopy, Inc. (Pink Sheets: ... revenues during the three months ended September 30, 2010 in ... ended September 30, 2009.  This was an increase of 34.8% for ... Despite a down global economy, Solos has been able ...
Cached Medicine Technology:Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 2Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 3Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010 2
(Date:7/31/2015)... ... ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, ... it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising ... will grant 100% of the money raised to BioViva to help bring pioneering gene ...
(Date:7/31/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Way, Oct. 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated ... it doesn’t have to. , Instead of risking containment — or even destruction ...
(Date:7/31/2015)... Tampa, FL (PRWEB) , ... July 31, 2015 ... ... cancer patients using the RenovoCath,™ a novel catheter that was developed for targeted ... locally-advanced pancreatic cancer are now being treated at Florida Hospital Tampa with the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National Team ... September 17th at Ford Field in Detroit and the second match will occur in ...
(Date:7/31/2015)... ... ... Indosoft, Inc., is pleased to announce a major update to its agent interface ... ACD system for Asterisk-based call centers . The new features make it easier ... agent only when wanted, and allows for validation of data as the agent enters ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... Accepts as Complete DNV,s ... Hospital Deeming Authority, HOUSTON, March 24 The U.S. ... that its application to,deem hospitals in compliance with the Medicare ... formal review., If approved, DNV stands to become the ...
... Control of all Sites from a Single ... ... Dayton,Ohio has chosen multiple products from Sage Software - including the,Intergy by ... and improve the,patient experience. Previously, Digestive Specialists used The Medical,Manager by Sage., ...
... March 24 MedCath Corporation,(MedCath) (Nasdaq: MDTH ... Ohio) jointly announced today that the parties have,entered ... Samaritan,Hospital will acquire substantially all of Dayton Heart ... $55.0 million, a portion of,which is allocated to ...
... they,re not getting needed screenings for breast and cervical tumors ... of 32 studies suggests that obese women -- particularly white ... for breast and cervical cancer. , No one knows ... mammograms or Pap smears. And it,s not known why obesity ...
... BOSTON, March 24 "Going head-to-head with your child,can be ... ask,for some extra reading at bedtime and, before you know ... that you can,t refuse.,Well, if I can,t stay up late ... I guess you owe me a back rub and two ...
... Joint ST/Veredus lab set up in Singapore to develop future lab-on-chip ... ... SINGAPORE, March 24 Following the,success of the evaluation trials conducted ... STM ) today announced the commercial availability,of VereFlu(TM), a portable ...
Cached Medicine News:Health News:DNV Healthcare Advances in Bid to Accredit Hospitals 2Health News:Multi-site Gastro Practice Chooses Intergy by Sage Practice Management System 2Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 2Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 3Health News:Obese Women Less Likely to Be Tested for Some Cancers 2Health News:HOW TO UNSPOIL YOUR CHILD FAST: Harvard Medical School Psychologist Writes Book to Guide and Motivate Parents and Support the Children's Defense Fund 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 3
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
Red Lens Maddox...
The Snellen chart is the default optotype with the standard order of letters (T Z V E C L) as default. When the Refresh 'R' button is pressed, the letters ( or pictures ) are replaced with a random s...
Snellen 20' Eye Test Chart....
Medicine Products: